Arrivo Bio initiates phase 2b trial of SIRT6 activator for major depressive disorder
Arrivo Bio has dosed the first patient in a phase 2b clinical trial of SP-624, a novel SIRT6 activator being evaluated as a treatment for major depressive disorder, the company announced in a press release.“Arrivo is at the forefront of clinical research with SIRT6 activators,” Arrivo co-founder and CEO Steve Butts, MBA, told Healio. “We have spent years learning about this